MicroQuin Secures Second DoD CDMRP Grant to Advance Ovarian Cancer Treatment Research

Ovarian cancer remains one of the most challenging cancers to treat, with survival rates lagging behind many other cancer types. The need for new, effective therapies is urgent. MicroQuin, a company dedicated to developing novel cancer treatments, has recently received its second grant from the Department of Defense’s Congressionally Directed Medical Research Programs (DoD CDMRP). This funding will support their ongoing efforts to develop promising new treatments for ovarian cancer.